Mexiletine Interactions

Class I antiarrhythmic; toxic effects are additive and potentially synergistic when used with lidocaine patch 5%.

Source: NLP:lidocaine

Class I antiarrhythmic; toxic effects are additive and potentially synergistic with lidocaine patch 5%.

Source: NLP:lidocaine 5%

Class I antiarrhythmic; toxic effects are additive and potentially synergistic when used with lidocaine and prilocaine cream.

Source: NLP:lidocaine and prilocaine

CYP1A2 inhibitor antiarrhythmic; concomitant use should be avoided due to potential for hypotension, bradycardia, or excessive drowsiness.

Source: NLP:tizanidine

Concomitant use should be avoided due to potential interactions. If clinically necessary, initiate with 2 mg and titrate cautiously.

Source: NLP:tizanidine hydrochloride

Should be avoided due to CYP1A2 inhibition. If necessary, initiate tizanidine at 2 mg and titrate cautiously; monitor for hypotension, bradycardia, or excessive drowsiness.

Source: NLP:tizanidne hydrochloride

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring

Source: NLP:warfarin

CYP1A2 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.

Source: NLP:warfarin sodium

Atropine Sulfate decreases the rate of mexiletine absorption without altering relative oral bioavailability. This delay can be reversed by combining atropine with intravenous metoclopramide.

Source: NLP:atropine sulfate

Atropine Sulfate Injection decreased the rate of mexiletine absorption without altering relative oral bioavailability. This delay was reversed by combination of atropine and intravenous metoclopramide.

Source: NLP:atropine sulfate injection

Class I antiarrhythmic drug; toxic effects are additive and potentially synergistic when used with lidocaine and capsaicin patch.

Source: NLP:lidocaine and capsaicin

Use with caution due to additive and potentially synergistic toxic effects when combined with lidocaine.

Source: NLP:menthol 5%, lidocaine 4%

Quinidine may affect mexiletine metabolism via cytochrome P450 IID6 inhibition; monitoring recommended.

Source: NLP:quinidine gluconate

Quinidine inhibits P450 IID6-dependent metabolism, potentially increasing mexiletine levels.

Source: NLP:quinidine sulfate tablet

CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.

Source: NLP:riluzole